P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma

Priming of PRAME- and WT1-specific CD8+T cells in healthy donors but not in AML patients in complete remission

(2013) Willemijn van den Ancker et al.   OncoImmunology

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination

(2011) Masanori Noguchi et al.   CANCER BIOLOGY & THERAPY

Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma

(2011) Eishiro Mizukoshi et al.   HEPATOLOGY

Potential targets for pancreatic cancer immunotherapeutics

(2011) Lindzy F Dodson et al.   Immunotherapy

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Major Molecular Markers in Pancreatic Ductal Adenocarcinoma and Their Roles in Screening, Diagnosis, Prognosis, and Treatment

(2011) Puneet Singh et al.   PANCREAS

Immunity, Inflammation, and Cancer

(2010) Sergei I. Grivennikov et al.   CELL

Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer

(2010) Miho Kaida et al.   JOURNAL OF IMMUNOTHERAPY

Pancreatic Cancer

(2010) Manuel Hidalgo   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer

(2009) Motoki Miyazawa et al.   CANCER SCIENCE

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

(2009) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation

(2008) D. Laheru et al.   CLINICAL CANCER RESEARCH